Sanofi sees pipeline fruition in 2018
December 13, 2017Research and Development Sanofi, biotech, drugs, pharma, pharmaceutical
In news that Sanofi will no doubt be hoping should divert attention away from the Dengvaxia scandal, the company revealed …
Blood cancer patients over 75 are significantly underrepresented in clinical trials, study finds
December 13, 2017Research and Development FDA, blood cancer, leukaemia, lymphoma, myeloid leukaemia, pharma
The FDA’s first comprehensive analysis of clinical trial enrolment in older patients with blood cancers has revealed that the population …
FDA cracks down on snortable chocolate powder
December 13, 2017Medical Communications, Research and Development FDA, biotech, drugs, pharma, pharmaceutical
The FDA has taken action on Coco Loko and Legal Lean Syrup, both made by Arco Globus Trading LLC, after …
J&J’s Darzalex cuts risk of disease progression and death by 50%, new study shows
December 13, 2017Research and Development Genmab, J&J, JJ, Janssen, Johnson & Johnson, darzalex, multiple myeloma, pharma
Johnson and Johnson has revealed data which demonstrates that Darzalex (daratumumab), when combined with a regimen of bortezomib, melphalan and …
Tumultuous times at Teva continue, with Chairman exit
December 13, 2017Medical Communications, Research and Development Teva, biotech, drugs, pharma, pharmaceutical
In the latest addition to a number of high profile exits from Teva, previous interim Chief Executive and the company’s …
FDA approves first short-acting, follow-on biologic of Lilly’s Humalog insulin product
December 12, 2017Manufacturing and Production, Sales and Marketing Admelog, FDA, Humalog, Sanofi, diabetes, insulin, pharma
The FDA has announced its approval of Sanofi’s Admelog (insulin lispro), the first follow-on biologic version of Eli Lilly’s Humalog …
Latest US company accused of price gouging, after 2,469% increase
December 12, 2017Manufacturing and Production, Sales and Marketing Avondale Pharmaceutical, Niacor, biotech, drugs, pharma, pharmaceutical
It seems that no matter how much bad press comes their way, certain pharmaceutical companies are more than happy to …
Single, high-dose vaccine could provide better protection against cholera outbreaks, new research shows
December 12, 2017Manufacturing and Production, Research and Development Africa, Asia, Caribbean, Cholera, Vaccine, paxvax, pharma
A team of researchers at the University of Maryland School of Medicine (UMSOM) has been assessing the effectiveness of a …
Sanofi issues US-wide recall for arthritis product, after adverse events
December 12, 2017Manufacturing and Production Sanofi, Synvisc-One, biotech, drugs, pharma, pharmaceutical
Sanofi has announced a recall of 12,380 syringes of its Synvisc-One product for the treatment of osteoarthritis, after it was …
Ionis scores huge breakthrough in Huntington’s, Roche licenses drug
December 12, 2017Manufacturing and Production, Research and Development Ionis, Roche, biotech, drugs, pharma, pharmaceutical
Ionis Pharmaceuticals has revealed findings from its Phase 1/2a study into a treatment for Huntington’s disease and the strong data …
Exscientia appoints Oxford Innovation Sciences founder and ex-Lansdowne CEO as Deputy Chairman
December 11, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alex Snow, Exscientia, appointment
Exscientia, an Oxford-based drug design firm which has made headlines this year for its collaboration with GlaxoSmithKline to leverage its …
To succeed in emerging market medicine, anticipation and innovation are essential
December 11, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbott, biotech, drugs, emerging markets, pharma, pharmaceutical
Andrew Lane, Executive Vice President of Established Pharmaceuticals at Abbott, discusses the key steps to be taken when reaching out …
FDA issued the fewest warnings over pharma advertising this year since 1997
December 11, 2017Sales and Marketing Amherst, FDA, advertising, cipher, orexigen, pharma
Throughout 2017, it has emerged that the FDA has issued a record low number of warning letters to pharmaceutical firms …
Cyramza fails to improve overall survival in gastric cancer, Lilly scraps regulatory plans
December 11, 2017Research and Development, Sales and Marketing Cancer, Eli Lilly, cyramza, gastric cancer, pharma
Eli Lilly has unveiled Phase 3 results which reveal that its VEGF Receptor 2 antagonist Cyramza (ramucirumab) met its primary …
Teva job cut rumours resurface, 10,000 expected
December 11, 2017Manufacturing and Production, Sales and Marketing Teva, biotech, drugs, pharma, pharmaceutical
Only last month, the story broke that Teva was looking to cut away a number of employees, the rumours have …
PhRMA launches lawsuit against the state of California over anti-price hike bill
December 11, 2017Sales and Marketing Drug pricing, PhRMA, california, pharma, price hikes
The state of California has become the target of legal action after the lobbying group Pharmaceutical Research and Manufacturers of …
NHS trust boss of major hospital hands in fiery resignation notice
December 11, 2017Medical Communications, Sales and Marketing NHS, biotech, drugs, pharma, pharmaceutical
Bob Kerslake, now former chair of King’s College hospital, London, has handed in his resignation, citing the lack of long-term …
Top Ten most popular articles on Pharmafile.com this week
December 8, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, drugs, most read news, pharma, pharmaceutical, top ten
Despite us nearing the end of the year, the news has not been slowing down at all. Headlines across Europe …
Roche Tecentriq combo effective, but is it enough?
December 8, 2017Medical Communications, Research and Development Roche, biotech, drugs, pharma, pharmaceutical, tecentriq
When Roche announced that its combination treatment of Tecentriq, alongside its own drug Avastin and chemotherapy, successfully extended progression-free survival …
Gilead makes $567m strategic acquisition for next-gen CAR-T
December 8, 2017Medical Communications, Sales and Marketing CAR-T, Cell Design Labs, Gilead, Kite, biotech, drugs, pharma, pharmaceutical
It’s only four months since Gilead completed its buy-out of Kite Pharma for $11.9 billion, but it’s already moving quickly …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
